{"id":"solifenacin-succinate-treatment","safety":{"commonSideEffects":[{"rate":"11-27%","effect":"Dry mouth"},{"rate":"9-15%","effect":"Constipation"},{"rate":"5-8%","effect":"Blurred vision"},{"rate":"1-2%","effect":"Urinary retention"},{"rate":"2-4%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200803","moleculeType":"Small molecule","molecularWeight":"480.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Solifenacin selectively blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing acetylcholine-induced contractions. This reduces urinary urgency and frequency, and increases bladder capacity. It is used to treat overactive bladder symptoms by suppressing the parasympathetic signaling that drives inappropriate bladder contractions.","oneSentence":"Solifenacin succinate is a muscarinic M3 receptor antagonist that reduces involuntary bladder muscle contractions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:54.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT07473310","phase":"PHASE4","title":"Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-11-11","conditions":"Overactive Bladder (OAB), Urge Incontinence","enrollment":70},{"nctId":"NCT01530373","phase":"PHASE2","title":"Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2012-02","conditions":"Hot Flashes, Breast Cancer","enrollment":110},{"nctId":"NCT07429734","phase":"PHASE3","title":"Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-02","conditions":"Overactive Bladder","enrollment":60},{"nctId":"NCT07305298","phase":"","title":"Mirabegron in Patients With Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"University of Naples","startDate":"2026-04-01","conditions":"Dry AMD, Overactive Bladder","enrollment":312},{"nctId":"NCT07337252","phase":"","title":"Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-01","conditions":"Overactive Bladder","enrollment":61},{"nctId":"NCT07312955","phase":"NA","title":"Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-05-15","conditions":"Overactive Bladder","enrollment":80},{"nctId":"NCT06465576","phase":"PHASE4","title":"Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-05-27","conditions":"Urinary Incontinence in Children","enrollment":216},{"nctId":"NCT06551246","phase":"PHASE3","title":"Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-06-27","conditions":"Urinary Incontinence in Children","enrollment":236},{"nctId":"NCT06110975","phase":"NA","title":"Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anne Estrup Olesen","startDate":"2023-12-01","conditions":"Overactive Bladder, Deprescribing, PIMS","enrollment":72},{"nctId":"NCT06489951","phase":"NA","title":"Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker","status":"COMPLETED","sponsor":"Xing Liu","startDate":"2024-12-28","conditions":"Overactive Bladder, Pediatric Disorder","enrollment":180},{"nctId":"NCT07199894","phase":"PHASE3","title":"Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-12-01","conditions":"Nocturnal Enuresis in Children","enrollment":120},{"nctId":"NCT07025642","phase":"NA","title":"Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes","status":"RECRUITING","sponsor":"Mackay Medical College","startDate":"2025-07-01","conditions":"Overactive Bladder (OAB)","enrollment":60},{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":"Radiation Cystitis","enrollment":40},{"nctId":"NCT05798403","phase":"NA","title":"Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder","status":"RECRUITING","sponsor":"Yin Ping","startDate":"2023-07-07","conditions":"Overactive Bladder","enrollment":204},{"nctId":"NCT05968885","phase":"PHASE4","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2021-10-01","conditions":"Urinary Bladder, Overactive, Urodynamics, Effect of Drug","enrollment":300},{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300},{"nctId":"NCT06528613","phase":"","title":"Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.","status":"RECRUITING","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2024-10-23","conditions":"Benign Prostatic Hyperplasia","enrollment":450},{"nctId":"NCT05067478","phase":"","title":"Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2021-10-28","conditions":"Overactive Bladder","enrollment":403},{"nctId":"NCT01021332","phase":"PHASE3","title":"Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2010-04-26","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":1067},{"nctId":"NCT01018511","phase":"PHASE3","title":"Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2010-01-11","conditions":"Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms","enrollment":1334},{"nctId":"NCT01093534","phase":"PHASE4","title":"Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01-19","conditions":"Detrusor Overactivity, Overactive Bladder","enrollment":547},{"nctId":"NCT01638000","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-06-12","conditions":"Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases","enrollment":1887},{"nctId":"NCT00629642","phase":"PHASE4","title":"Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-14","conditions":"Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases","enrollment":249},{"nctId":"NCT01655069","phase":"PHASE3","title":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-04","conditions":"Urinary Bladder, Overactive","enrollment":148},{"nctId":"NCT02294396","phase":"PHASE4","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-28","conditions":"Overactive Bladder (OAB)","enrollment":649},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":"Urinary Bladder Overactive, Urinary Bladder Diseases\\Urologic Diseases, Overactive Bladder","enrollment":3527},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":"Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases","enrollment":2174},{"nctId":"NCT01565707","phase":"PHASE3","title":"A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-06-07","conditions":"Urinary Bladder, Overactive","enrollment":189},{"nctId":"NCT02045862","phase":"PHASE3","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-17","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence","enrollment":1829},{"nctId":"NCT01981954","phase":"PHASE3","title":"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09-25","conditions":"Neurogenic Detrusor Overactivity, Pediatric","enrollment":23},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":"Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations","enrollment":1307},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":"Overactive Bladder (OAB)","enrollment":5589},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT04819360","phase":"PHASE4","title":"Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis","status":"TERMINATED","sponsor":"Brigitte Schürch","startDate":"2021-06-01","conditions":"Urinary Bladder, Neurogenic, Multiple Sclerosis","enrollment":1},{"nctId":"NCT03149809","phase":"PHASE3","title":"Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-03-01","conditions":"Overactive Bladder, Parkinson Disease","enrollment":77},{"nctId":"NCT05282069","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2022-05-12","conditions":"Overactive Bladder","enrollment":607},{"nctId":"NCT03106623","phase":"PHASE2","title":"Study of ONO-8577 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-04-07","conditions":"Overactive Bladder","enrollment":207},{"nctId":"NCT06184334","phase":"NA","title":"Management of OAB in Female Patients .","status":"COMPLETED","sponsor":"Elsayed Abdelhalim Elsayed","startDate":"2022-09-14","conditions":"Overactive Bladder","enrollment":300},{"nctId":"NCT05709990","phase":"NA","title":"Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children","status":"COMPLETED","sponsor":"Xing Liu","startDate":"2023-01-15","conditions":"Overactive Bladder","enrollment":303},{"nctId":"NCT03817931","phase":"PHASE4","title":"Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2019-08-05","conditions":"Overactive Bladder, Dementia, Lower Urinary Tract Symptoms","enrollment":12},{"nctId":"NCT06201013","phase":"NA","title":"Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children","status":"UNKNOWN","sponsor":"Xing Liu","startDate":"2023-09-03","conditions":"Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge","enrollment":150},{"nctId":"NCT04023253","phase":"PHASE3","title":"Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2019-08-01","conditions":"Overactive Bladder Syndrome","enrollment":120},{"nctId":"NCT06024005","phase":"NA","title":"Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder","status":"COMPLETED","sponsor":"Ege University","startDate":"2023-04-18","conditions":"Overactive Bladder, Overactive Bladder Syndrome","enrollment":34},{"nctId":"NCT05911594","phase":"NA","title":"IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-02-14","conditions":"BOTOX, Percutaneous Tibial Nerve Stimulation","enrollment":128},{"nctId":"NCT04437108","phase":"NA","title":"Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2020-07-04","conditions":"Overactive Bladder, Urinary Incontinence, Urge, Urgency-frequency Syndrome","enrollment":132},{"nctId":"NCT02540707","phase":"PHASE4","title":"Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-09-08","conditions":"Overactive Bladder Syndrome","enrollment":113},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":"Urinary Incontinence, Urgency Urinary","enrollment":20},{"nctId":"NCT05494567","phase":"PHASE4","title":"Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-11-08","conditions":"Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":60},{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":"Voiding Disorders","enrollment":100},{"nctId":"NCT00852696","phase":"NA","title":"Over Active Bladder Patients Having Sling Surgery","status":"TERMINATED","sponsor":"Cleveland Clinic Florida","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":1},{"nctId":"NCT05391425","phase":"","title":"The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function","status":"UNKNOWN","sponsor":"Istanbul University","startDate":"2021-06-03","conditions":"Urge Incontinence, Urgency-frequency Syndrome","enrollment":150},{"nctId":"NCT05240456","phase":"PHASE1, PHASE2","title":"Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-02","conditions":"Voiding Disorders, Overactive Bladder","enrollment":70},{"nctId":"NCT03787654","phase":"NA","title":"Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-03-01","conditions":"Mixed Urinary Incontinence, Urgency-predominant Mixed Urinary Incontinence","enrollment":282},{"nctId":"NCT04325880","phase":"PHASE3","title":"Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-12-01","conditions":"Ureteral Stent, Stent Related Symptoms","enrollment":240},{"nctId":"NCT01018264","phase":"PHASE4","title":"Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2010-01","conditions":"Overactive Bladder in Parkinson's Disease","enrollment":23},{"nctId":"NCT04909255","phase":"PHASE4","title":"Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2021-03-23","conditions":"Sjogren's Syndrome, Overactive Bladder Syndrome","enrollment":50},{"nctId":"NCT04693897","phase":"","title":"Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-01","conditions":"Overactive Bladder Syndrome, Detrusor Overactivity","enrollment":400},{"nctId":"NCT03572231","phase":"","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-19","conditions":"Overactive Bladder (OAB)","enrollment":805},{"nctId":"NCT03566134","phase":"PHASE2","title":"A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2018-07-10","conditions":"Overactive Bladder","enrollment":306},{"nctId":"NCT01559389","phase":"PHASE4","title":"Incontinence & Intimate Partners: Assessing the Contribution of Treatment","status":"COMPLETED","sponsor":"Loyola University","startDate":"2012-03-09","conditions":"Urge Urinary Incontinence","enrollment":138},{"nctId":"NCT01499069","phase":"NA","title":"Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-02","conditions":"Overactive Bladder","enrollment":191},{"nctId":"NCT02972268","phase":"PHASE3","title":"Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-02-01","conditions":"Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia","enrollment":780},{"nctId":"NCT02047032","phase":"NA","title":"Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2014-04","conditions":"Urinary Incontinence","enrollment":500},{"nctId":"NCT01767519","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-03-01","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":356},{"nctId":"NCT03662893","phase":"NA","title":"Behavioural Therapy With Checklist for Overactive Bladder","status":"COMPLETED","sponsor":"Ankara Training and Research Hospital","startDate":"2015-01-01","conditions":"Overactive Bladder","enrollment":120},{"nctId":"NCT03632772","phase":"PHASE2","title":"Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2018-08-01","conditions":"Overactive Bladder Syndrome","enrollment":130},{"nctId":"NCT03468465","phase":"PHASE4","title":"Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome","status":"UNKNOWN","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2018-05-04","conditions":"Urinary Incontinence","enrollment":110},{"nctId":"NCT03558919","phase":"PHASE4","title":"Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2017-01-01","conditions":"Overactive Bladder","enrollment":81},{"nctId":"NCT01166438","phase":"PHASE3","title":"Anticholinergic vs. Botox Comparison Study","status":"COMPLETED","sponsor":"NICHD Pelvic Floor Disorders Network","startDate":"2010-03","conditions":"Urge Urinary Incontinence, Overactive Bladder","enrollment":249},{"nctId":"NCT00821184","phase":"PHASE3","title":"Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2006-09","conditions":"Overactive Bladder","enrollment":12},{"nctId":"NCT01457573","phase":"PHASE4","title":"Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Timothy Boone, MD, PhD","startDate":"2011-10","conditions":"Lower Urinary Tract Symptoms","enrollment":10},{"nctId":"NCT01745094","phase":"PHASE4","title":"A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10-01","conditions":"Overactive Bladder","enrollment":223},{"nctId":"NCT02805452","phase":"PHASE3","title":"Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer","status":"TERMINATED","sponsor":"Center Eugene Marquis","startDate":"2016-07","conditions":"Overactive Bladder","enrollment":4},{"nctId":"NCT00547378","phase":"PHASE4","title":"InSite for Over Active Bladder","status":"COMPLETED","sponsor":"MedtronicNeuro","startDate":"2007-10","conditions":"Urinary Incontinence, Urgency-frequency, Overactive Bladder","enrollment":571},{"nctId":"NCT02129816","phase":"PHASE2, PHASE3","title":"Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2014-05","conditions":"Overactive Bladder, Urge Urinary Incontinence","enrollment":9},{"nctId":"NCT02860065","phase":"PHASE2","title":"CPC-201 Alzheimer's Disease Type Dementia: PET Study","status":"WITHDRAWN","sponsor":"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc","startDate":"2016-09-30","conditions":"Alzheimer's Disease","enrollment":""},{"nctId":"NCT00909428","phase":"PHASE4","title":"Validation of a Real-time Urodynamic Measure of Urinary Urgency","status":"COMPLETED","sponsor":"Loyola University","startDate":"2007-01","conditions":"Overactive Bladder Syndrome","enrollment":51},{"nctId":"NCT03059134","phase":"PHASE3","title":"Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2015-04-28","conditions":"Urinary Incontinence, Overactive Bladder Syndrome","enrollment":168},{"nctId":"NCT01486706","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Gabapentin in Treating Overactive Bladder","status":"COMPLETED","sponsor":"Michael E. Chua","startDate":"2010-10","conditions":"Urinary Urgency, Urinary Frequency, Nocturia","enrollment":94},{"nctId":"NCT00773552","phase":"PHASE4","title":"Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder","status":"WITHDRAWN","sponsor":"Stamford Hospital","startDate":"2008-11","conditions":"Urinary Urge, Urge Incontinence, Overactive Bladder","enrollment":""},{"nctId":"NCT02940314","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-03","conditions":"Overactive Bladder","enrollment":36},{"nctId":"NCT02087098","phase":"","title":"A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-06","conditions":"Urinary Bladder, Overactive","enrollment":2000},{"nctId":"NCT02845648","phase":"","title":"Ability to Awaken in Nonmonosymptomatic Enuresis","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-07","conditions":"Enuresis, Nocturnal, 2 (Disorder)","enrollment":119},{"nctId":"NCT02827578","phase":"PHASE3","title":"Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-01","conditions":"Benign Prostate Hyperplasia","enrollment":588},{"nctId":"NCT02180997","phase":"PHASE1","title":"Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2014-07","conditions":"LUTS, Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":36},{"nctId":"NCT02494349","phase":"PHASE1","title":"The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2015-08","conditions":"LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":54},{"nctId":"NCT01314781","phase":"PHASE4","title":"Therapy of the Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Cantonal Hospital, Frauenfeld","startDate":"2012-01","conditions":"Overactive Bladder","enrollment":66},{"nctId":"NCT02715024","phase":"PHASE4","title":"Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms","status":"COMPLETED","sponsor":"Astellas Pharma Taiwan, Inc.","startDate":"2007-09","conditions":"Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH)","enrollment":52},{"nctId":"NCT02667470","phase":"PHASE4","title":"Reproducibility Study of OABSS and Its Response to Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09","conditions":"Overactive Bladder","enrollment":50},{"nctId":"NCT00884104","phase":"PHASE4","title":"A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks","status":"COMPLETED","sponsor":"KYU-SUNG LEE","startDate":"2009-03","conditions":"Overactive Bladder","enrollment":307},{"nctId":"NCT02634489","phase":"PHASE1","title":"EC905 Pharmacokinetic Profile Study","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2009-03","conditions":"Phase 1, Healthy, Benign Prostatic Hyperplasia","enrollment":46},{"nctId":"NCT01642277","phase":"PHASE2","title":"Bacterial Genomic Sequencing in Overactive Bladder","status":"COMPLETED","sponsor":"Loyola University","startDate":"2012-07","conditions":"Overactive Bladder","enrollment":134},{"nctId":"NCT01880619","phase":"PHASE4","title":"Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2013-01","conditions":"Relieve of Ureteral Stent Symptoms","enrollment":131},{"nctId":"NCT01876186","phase":"PHASE4","title":"Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-05","conditions":"Overactive Bladder Syndrome","enrollment":200},{"nctId":"NCT02452879","phase":"NA","title":"Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2014-10","conditions":"Overactive Bladder","enrollment":180},{"nctId":"NCT01737918","phase":"PHASE1, PHASE2","title":"Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa","status":"UNKNOWN","sponsor":"Klinikum der Universität Köln","startDate":"2013-01","conditions":"Surgical Treatment of Urge Incontinence","enrollment":120},{"nctId":"NCT01737411","phase":"PHASE1, PHASE2","title":"Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women","status":"UNKNOWN","sponsor":"Klinikum der Universität Köln","startDate":"2013-01","conditions":"Urge Urinary Incontinence","enrollment":120},{"nctId":"NCT01777217","phase":"PHASE4","title":"VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate","status":"TERMINATED","sponsor":"Advanced Research Network","startDate":"2013-02","conditions":"Over-Active Bladder","enrollment":8},{"nctId":"NCT00454740","phase":"PHASE3","title":"Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Urinary Bladder, Overactive","enrollment":441}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VESIcare"],"phase":"marketed","status":"active","brandName":"Solifenacin succinate treatment","genericName":"Solifenacin succinate treatment","companyName":"Barrie Urology Associates","companyId":"barrie-urology-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Solifenacin succinate is a muscarinic M3 receptor antagonist that reduces involuntary bladder muscle contractions. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}